vs
ABVC BIOPHARMA, INC.（ABVC）与阿斯利康（AZN）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是ABVC BIOPHARMA, INC.的18163.2倍（$14.5B vs $796.0K）。阿斯利康净利率更高（16.9% vs -256.6%，领先273.5%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs 11.7%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
ABVC vs AZN — 直观对比
营收规模更大
AZN
是对方的18163.2倍
$796.0K
营收增速更快
ABVC
高出92.7%
11.7%
净利率更高
AZN
高出273.5%
-256.6%
损益表 — Q3 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $14.5B |
| 净利润 | $-2.0M | $2.4B |
| 毛利率 | 100.0% | 82.9% |
| 营业利润率 | -246.8% | 24.3% |
| 净利率 | -256.6% | 16.9% |
| 营收同比 | 104.5% | 11.7% |
| 净利润同比 | -417.4% | 27.0% |
| 每股收益（稀释后） | $-0.09 | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCAZN
| Q3 25 | $796.0K | — | ||
| Q2 25 | — | $14.5B | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | — | ||
| Q2 24 | $117.1K | $12.9B | ||
| Q1 24 | $1.2K | — | ||
| Q4 23 | $2.2K | — | ||
| Q3 23 | $15.9K | — |
净利润ABVCAZN
| Q3 25 | $-2.0M | — | ||
| Q2 25 | — | $2.4B | ||
| Q4 24 | $-731.6K | — | ||
| Q3 24 | $-394.8K | — | ||
| Q2 24 | $-942.3K | $1.9B | ||
| Q1 24 | $-2.8M | — | ||
| Q4 23 | $-383.3K | — | ||
| Q3 23 | $-3.3M | — |
毛利率ABVCAZN
| Q3 25 | 100.0% | — | ||
| Q2 25 | — | 82.9% | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | 83.1% | ||
| Q1 24 | 77.0% | — | ||
| Q4 23 | -6329.8% | — | ||
| Q3 23 | -86.4% | — |
营业利润率ABVCAZN
| Q3 25 | -246.8% | — | ||
| Q2 25 | — | 24.3% | ||
| Q4 24 | -35837.4% | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | 21.2% | ||
| Q1 24 | -235539.8% | — | ||
| Q4 23 | -23641.3% | — | ||
| Q3 23 | -13566.3% | — |
净利率ABVCAZN
| Q3 25 | -256.6% | — | ||
| Q2 25 | — | 16.9% | ||
| Q4 24 | -37211.3% | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | 14.9% | ||
| Q1 24 | -235203.2% | — | ||
| Q4 23 | -17705.7% | — | ||
| Q3 23 | -20885.9% | — |
每股收益（稀释后）ABVCAZN
| Q3 25 | $-0.09 | — | ||
| Q2 25 | — | $1.57 | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.08 | $1.24 | ||
| Q1 24 | $-0.29 | — | ||
| Q4 23 | $0.25 | — | ||
| Q3 23 | $-0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $7.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $44.8B |
| 总资产 | $21.2M | $112.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCAZN
| Q3 25 | $257.2K | — | ||
| Q2 25 | — | $7.1B | ||
| Q4 24 | $313.1K | — | ||
| Q3 24 | $208.2K | — | ||
| Q2 24 | $200.0K | $6.9B | ||
| Q1 24 | $106.4K | — | ||
| Q4 23 | $139.5K | — | ||
| Q3 23 | $568.6K | — |
股东权益ABVCAZN
| Q3 25 | $12.1M | — | ||
| Q2 25 | — | $44.8B | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | $1.8M | $39.6B | ||
| Q1 24 | $1.7M | — | ||
| Q4 23 | $1.6M | — | ||
| Q3 23 | $9.1M | — |
总资产ABVCAZN
| Q3 25 | $21.2M | — | ||
| Q2 25 | — | $112.4B | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $8.0M | $104.3B | ||
| Q1 24 | $8.0M | — | ||
| Q4 23 | $7.8M | — | ||
| Q3 23 | $16.6M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABVCAZN
| Q3 25 | $-964.7K | — | ||
| Q2 25 | — | — | ||
| Q4 24 | $-702.1K | — | ||
| Q3 24 | $60.2K | — | ||
| Q2 24 | $-211.4K | — | ||
| Q1 24 | $-955.8K | — | ||
| Q4 23 | $-430.5K | — | ||
| Q3 23 | $-1.4M | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
